3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leiomyosarcoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostate Cancer Metastatic
1
Mesothelioma, Malignant
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Interventions
pembrolizumab
31
Gemcitabine
26
Nivolumab
20
atezolizumab
16
Cisplatin
15
avelumab
14
Carboplatin
12
Docetaxel
10
enfortumab vedotin
8
Magnetic Resonance Spectroscopy
8
durvalumab
7
Specimen Handling
7
Paclitaxel
7
Ipilimumab
6
toripalimab
5
pemigatinib
5
cabozantinib
5
vinflunine
4
sacituzumab govitecan
4
Taxes
4
Pemetrexed
4
tislelizumab
3
cabazitaxel
3
Standard of Care
3
Mitomycin
3
Injections
3
Everolimus
3
Albumin-Bound Paclitaxel
3
sapanisertib
2
olaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Transitional Cell
×
rucaparib
×
Clear all
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts